Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic RESOLUTE

This article was originally published in The Gray Sheet

Executive Summary

Medtronic initiates a 100-patient, multi-site, first-in-man trial of its Endeavor CR controlled-release, ABT-578-eluting stent in Australia and New Zealand, the firm announces Dec. 13. The stent uses a new slow-release polymer, which could benefit patients with diabetes or complex lesions, the firm says. Medtronic filed its first PMA module for Endeavor in November and expects approval in 2007 (1"The Gray Sheet" Oct. 24, 2005, p. 4)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023034

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel